Affimed NV
NASDAQ:AFMD

Watchlist Manager
Affimed NV Logo
Affimed NV
NASDAQ:AFMD
Watchlist
Price: 0.1815 USD -34.95% Market Closed
Market Cap: 750k USD

AFMD's latest stock split occurred on Mar 11, 2024

The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.

Before the split, AFMD traded at 0.6079 per share. Afterward, the share price was about 5.38.

The adjusted shares began trading on Mar 11, 2024. This was the only stock split in AFMD's history.

Last Splits:
Mar 11, 2024
1-for-10
Pre-Split Price
6.079 0.6079
Post-Split Price
5.38
Before
After
Last Splits:
Mar 11, 2024
1-for-10

Affimed NV
Stock Splits History

AFMD Stock Splits Timeline
Mar 11, 2024
Mar 11, 2024
Split 1-for-10
/0.1
Pre-Split Price
6.079 0.6079
Post-Split Price
5.38
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

Affimed NV
Glance View

Market Cap
750k USD
Industry
Biotechnology

Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

AFMD Intrinsic Value
Not Available
Back to Top